Free shipping on all orders over $ 500

DCC-2618

Cat. No. M20635

All AbMole products are for research use only, cannot be used for human consumption.

DCC-2618 Structure

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of KIT and PDGFR with potential antineoplastic activity. It also inhibits several other kinases, including VEGFR2, TIE2, PDGFR-beta and CSF1R, thereby further inhibiting tumor cell growth.

Chemical Information
Molecular Weight 489.47
Formula C26H21F2N5O3
CAS Number 1225278-16-9
Solubility (25°C) DMSO 97 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] No authors listed. Ripretinib

[2] Andreas Reiter, et al. Blood. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

[3] Bryan D Smith, et al. Cancer Cell. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

[4] Mathias Schneeweiss, et al. Haematologica. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

[5] No authors listed. Cancer Discov. BLU-285, DCC-2618 Show Activity against GIST

Related c-Kit Products
Labuxtinib

Labuxtinib is c-kit tyrosine kinase inhibitor.

Elenestinib phosphate

Elenestinib phosphate (BLU-263 phosphate) is a potent and orally active tyrosine kinase inhibitor. Elenestinib phosphate has the potential for the research of systemic mastocytosis (SM).

Elenestinib

Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor. Elenestinib has the potential for the research of systemic mastocytosis (SM).

Bezuclastinib

Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 < IC50 < 1 μM). Bezuclastinib is a tyrosine kinase inhibitor.

Amuvatinib hydrochloride

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: DCC-2618 supplier, c-Kit, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.